Skip to main content
Erschienen in: Abdominal Radiology 1/2019

31.07.2018

Predictive role of PI-RADSv2 and ADC parameters in differentiating Gleason pattern 3 + 4 and 4 + 3 prostate cancer

verfasst von: Francesco Alessandrino, Mehdi Taghipour, Elmira Hassanzadeh, Alireza Ziaei, Mark Vangel, Andriy Fedorov, Clare M. Tempany, Fiona M. Fennessy

Erschienen in: Abdominal Radiology | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To compare the predictive roles of qualitative (PI-RADSv2) and quantitative assessment (ADC metrics), in differentiating Gleason pattern (GP) 3 + 4 from the more aggressive GP 4 + 3 prostate cancer (PCa) using radical prostatectomy (RP) specimen as the reference standard.

Methods

We retrospectively identified treatment-naïve peripheral (PZ) and transitional zone (TZ) Gleason Score 7 PCa patients who underwent multiparametric 3T prostate MRI (DWI with b value of 0,1400 and where unavailable, 0,500) and subsequent RP from 2011 to 2015. For each lesion identified on MRI, a PI-RADSv2 score was assigned by a radiologist blinded to pathology data. A PI-RADSv2 score ≤ 3 was defined as “low risk,” a PI-RADSv2 score ≥ 4 as “high risk” for clinically significant PCa. Mean tumor ADC (ADCT), ADC of adjacent normal tissue (ADCN), and ADCratio (ADCT/ADCN) were calculated. Stepwise regression analysis using tumor location, ADCT and ADCratio, b value, low vs. high PI-RADSv2 score was performed to differentiate GP 3 + 4 from 4 + 3.

Results

119 out of 645 cases initially identified met eligibility requirements. 76 lesions were GP 3 + 4, 43 were 4 + 3. ADCratio was significantly different between the two GP groups (p = 0.001). PI-RADSv2 score (“low” vs. “high”) was not significantly different between the two GP groups (p = 0.17). Regression analysis selected ADCT (p = 0.03) and ADCratio (p = 0.0007) as best predictors to differentiate GP 4 + 3 from 3 + 4. Estimated sensitivity, specificity, and accuracy of the predictive model in differentiating GP 4 + 3 from 3 + 4 were 37, 82, and 66%, respectively.

Conclusions

ADC metrics could differentiate GP 3 + 4 from 4 + 3 PCa with high specificity and moderate accuracy while PI-RADSv2, did not differentiate between these patterns.
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30CrossRef Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30CrossRef
2.
Zurück zum Zitat Quinn DI, Henshall SM, Haynes AM, et al. (2001) Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol 19(16):3692–3705PubMedCrossRef Quinn DI, Henshall SM, Haynes AM, et al. (2001) Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol 19(16):3692–3705PubMedCrossRef
3.
Zurück zum Zitat Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111(1):58–64PubMedCrossRef Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111(1):58–64PubMedCrossRef
4.
Zurück zum Zitat Andrén O, Fall K, Franzén L, et al. (2006) How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 175(4):1337–1340PubMedCrossRef Andrén O, Fall K, Franzén L, et al. (2006) How well does the Gleason score predict prostate cancer death? A 20-year followup of a population based cohort in Sweden. J Urol 175(4):1337–1340PubMedCrossRef
5.
Zurück zum Zitat Stark JR, Perner S, Stampfer MJ, et al. (2009) Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27(21):3459–3464PubMedPubMedCentralCrossRef Stark JR, Perner S, Stampfer MJ, et al. (2009) Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27(21):3459–3464PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Epstein JI, Zelefsky MJ, Sjoberg DD, et al. (2016) A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 69(3):428–435PubMedCrossRef Epstein JI, Zelefsky MJ, Sjoberg DD, et al. (2016) A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 69(3):428–435PubMedCrossRef
7.
Zurück zum Zitat Kane CJ, Eggener SE, Shindel AW, Andriole GL (2017) Variability in outcomes for patients with intermediate-risk prostate cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2–3) and implications for risk stratification: a systematic review. Eur Urol Focus 3(4–5):487–497PubMedCrossRef Kane CJ, Eggener SE, Shindel AW, Andriole GL (2017) Variability in outcomes for patients with intermediate-risk prostate cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2–3) and implications for risk stratification: a systematic review. Eur Urol Focus 3(4–5):487–497PubMedCrossRef
8.
Zurück zum Zitat Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee (2016) The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40(2):244–252 Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee (2016) The 2014 International Society of Urological Pathology (ISUP) consensus conference on gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 40(2):244–252
9.
Zurück zum Zitat Hoeks CMA, Barentsz JO, Hambrock T, et al. (2011) Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 261(1):46–66PubMedCrossRef Hoeks CMA, Barentsz JO, Hambrock T, et al. (2011) Prostate cancer: multiparametric MR imaging for detection, localization, and staging. Radiology 261(1):46–66PubMedCrossRef
10.
Zurück zum Zitat Jambor I, Boström PJ, Taimen P, et al. (2017) Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). J Magn Reson Imaging 46(4):1089–1095PubMedCrossRef Jambor I, Boström PJ, Taimen P, et al. (2017) Novel biparametric MRI and targeted biopsy improves risk stratification in men with a clinical suspicion of prostate cancer (IMPROD Trial). J Magn Reson Imaging 46(4):1089–1095PubMedCrossRef
11.
Zurück zum Zitat Wu L-M, Xu J-R, Ye Y-Q, Lu Q, Hu J-N (2012) The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: a systematic review and meta-analysis. AJR 199(1):103–110PubMedCrossRef Wu L-M, Xu J-R, Ye Y-Q, Lu Q, Hu J-N (2012) The clinical value of diffusion-weighted imaging in combination with T2-weighted imaging in diagnosing prostate carcinoma: a systematic review and meta-analysis. AJR 199(1):103–110PubMedCrossRef
12.
Zurück zum Zitat Weinreb JC, Barentsz JO, Choyke PL, et al. (2016) PI-RADS prostate imaging—reporting and data system: 2015, Version 2. Eur Urol 69(1):16–40PubMedCrossRef Weinreb JC, Barentsz JO, Choyke PL, et al. (2016) PI-RADS prostate imaging—reporting and data system: 2015, Version 2. Eur Urol 69(1):16–40PubMedCrossRef
13.
Zurück zum Zitat Hambrock T, Somford DM, Huisman HJ, et al. (2011) Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 259(2):453–461PubMedCrossRef Hambrock T, Somford DM, Huisman HJ, et al. (2011) Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer. Radiology 259(2):453–461PubMedCrossRef
14.
Zurück zum Zitat De Cobelli F, Ravelli S, Esposito A, et al. (2015) Apparent diffusion coefficient value and ratio as noninvasive potential biomarkers to predict prostate cancer grading: comparison with prostate biopsy and radical prostatectomy specimen. AJR 204(3):550–557PubMedCrossRef De Cobelli F, Ravelli S, Esposito A, et al. (2015) Apparent diffusion coefficient value and ratio as noninvasive potential biomarkers to predict prostate cancer grading: comparison with prostate biopsy and radical prostatectomy specimen. AJR 204(3):550–557PubMedCrossRef
15.
Zurück zum Zitat Woo S, Kim SY, Cho JY, Kim SH (2016) Preoperative evaluation of prostate cancer aggressiveness: using ADC and ADC ratio in determining gleason score. AJR 207(1):114–120PubMedCrossRef Woo S, Kim SY, Cho JY, Kim SH (2016) Preoperative evaluation of prostate cancer aggressiveness: using ADC and ADC ratio in determining gleason score. AJR 207(1):114–120PubMedCrossRef
16.
Zurück zum Zitat Barrett T, Priest AN, Lawrence EM, et al. (2015) Ratio of tumor to normal prostate tissue apparent diffusion coefficient as a method for quantifying DWI of the prostate. AJR 205(6):W585–593PubMedCrossRef Barrett T, Priest AN, Lawrence EM, et al. (2015) Ratio of tumor to normal prostate tissue apparent diffusion coefficient as a method for quantifying DWI of the prostate. AJR 205(6):W585–593PubMedCrossRef
17.
Zurück zum Zitat Litjens GJS, Hambrock T, Hulsbergen-van de Kaa C, Barentsz JO, Huisman HJ (2012) Interpatient variation in normal peripheral zone apparent diffusion coefficient: effect on the prediction of prostate cancer aggressiveness. Radiology 265(1):260–266PubMedCrossRef Litjens GJS, Hambrock T, Hulsbergen-van de Kaa C, Barentsz JO, Huisman HJ (2012) Interpatient variation in normal peripheral zone apparent diffusion coefficient: effect on the prediction of prostate cancer aggressiveness. Radiology 265(1):260–266PubMedCrossRef
18.
Zurück zum Zitat Peng Y, Jiang Y, Antic T, et al. (2014) Apparent diffusion coefficient for prostate cancer imaging: impact of b values. AJR 202(3):W247–253PubMedCrossRef Peng Y, Jiang Y, Antic T, et al. (2014) Apparent diffusion coefficient for prostate cancer imaging: impact of b values. AJR 202(3):W247–253PubMedCrossRef
19.
Zurück zum Zitat Rosenkrantz AB, Triolo MJ, Melamed J, et al. (2014) Whole-lesion apparent diffusion coefficient metrics as a marker of percentage Gleason 4 component within Gleason 7 prostate cancer at radical prostatectomy. J Magn Reson Imaging 41(3):708–714PubMedPubMedCentralCrossRef Rosenkrantz AB, Triolo MJ, Melamed J, et al. (2014) Whole-lesion apparent diffusion coefficient metrics as a marker of percentage Gleason 4 component within Gleason 7 prostate cancer at radical prostatectomy. J Magn Reson Imaging 41(3):708–714PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Itou Y, Nakanishi K, Narumi Y, Nishizawa Y, Tsukuma H (2011) Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer? J Magn Reson Imaging 33(1):167–172PubMedCrossRef Itou Y, Nakanishi K, Narumi Y, Nishizawa Y, Tsukuma H (2011) Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: can ADC values contribute to assess the aggressiveness of prostate cancer? J Magn Reson Imaging 33(1):167–172PubMedCrossRef
22.
Zurück zum Zitat Park SY, Jung DC, Oh YT, et al. (2016) Prostate cancer: pI-RADS version 2 helps preoperatively predict clinically significant cancers. Radiology 280(1):151133CrossRef Park SY, Jung DC, Oh YT, et al. (2016) Prostate cancer: pI-RADS version 2 helps preoperatively predict clinically significant cancers. Radiology 280(1):151133CrossRef
23.
Zurück zum Zitat Hegde JV, Mulkern RV, Panych LP, et al. (2013) Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging 37(5):1035–1054PubMedPubMedCentralCrossRef Hegde JV, Mulkern RV, Panych LP, et al. (2013) Multiparametric MRI of prostate cancer: an update on state-of-the-art techniques and their performance in detecting and localizing prostate cancer. J Magn Reson Imaging 37(5):1035–1054PubMedPubMedCentralCrossRef
24.
Zurück zum Zitat Hassanzadeh E, Alessandrino F, Olubiyi OI, et al. (2017) Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer. Abdom Radiol (NY) 43(5):1237–12425CrossRef Hassanzadeh E, Alessandrino F, Olubiyi OI, et al. (2017) Comparison of quantitative apparent diffusion coefficient parameters with prostate imaging reporting and data system V2 assessment for detection of clinically significant peripheral zone prostate cancer. Abdom Radiol (NY) 43(5):1237–12425CrossRef
25.
Zurück zum Zitat Fennessy FM, Fedorov A, Penzkofer T, et al. (2015) Quantitative pharmacokinetic analysis of prostate cancer DCE-MRI at 3T: comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation. Magn Reson Imaging. 33(7):886–894PubMedPubMedCentralCrossRef Fennessy FM, Fedorov A, Penzkofer T, et al. (2015) Quantitative pharmacokinetic analysis of prostate cancer DCE-MRI at 3T: comparison of two arterial input functions on cancer detection with digitized whole mount histopathological validation. Magn Reson Imaging. 33(7):886–894PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Srigley JR, Humphrey PA, Amin MB, et al. (2009) Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med 133(10):1568–1576PubMed Srigley JR, Humphrey PA, Amin MB, et al. (2009) Protocol for the examination of specimens from patients with carcinoma of the prostate gland. Arch Pathol Lab Med 133(10):1568–1576PubMed
27.
Zurück zum Zitat Buyyounouski MK, Choyke PL, Kattan MW, et al. (2017) Prostate. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. (eds) AJCC Cancer Staging Manual, 8th edn. New York: Springer, pp 715–726 Buyyounouski MK, Choyke PL, Kattan MW, et al. (2017) Prostate. In: Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, et al. (eds) AJCC Cancer Staging Manual, 8th edn. New York: Springer, pp 715–726
28.
Zurück zum Zitat Nowak J, Malzahn U, Baur ADJ, et al. (2014) The value of ADC, T2 signal intensity, and a combination of both parameters to assess Gleason score and primary Gleason grades in patients with known prostate cancer. Acta Radiol 7(1):107–114CrossRef Nowak J, Malzahn U, Baur ADJ, et al. (2014) The value of ADC, T2 signal intensity, and a combination of both parameters to assess Gleason score and primary Gleason grades in patients with known prostate cancer. Acta Radiol 7(1):107–114CrossRef
29.
Zurück zum Zitat Jyoti R, Jain TP, Haxhimolla H, Liddell H, Barrett SE (2018) Correlation of apparent diffusion coefficient ratio on 3.0 T MRI with prostate cancer Gleason score. Eur J Radiol Open 5:58–63PubMedPubMedCentralCrossRef Jyoti R, Jain TP, Haxhimolla H, Liddell H, Barrett SE (2018) Correlation of apparent diffusion coefficient ratio on 3.0 T MRI with prostate cancer Gleason score. Eur J Radiol Open 5:58–63PubMedPubMedCentralCrossRef
30.
Zurück zum Zitat Lebovici A, Sfrangeu SA, Feier D, et al. (2014) Evaluation of the normal-to-diseased apparent diffusion coefficient ratio as an indicator of prostate cancer aggressiveness. BMC Med Imaging 14:15PubMedPubMedCentralCrossRef Lebovici A, Sfrangeu SA, Feier D, et al. (2014) Evaluation of the normal-to-diseased apparent diffusion coefficient ratio as an indicator of prostate cancer aggressiveness. BMC Med Imaging 14:15PubMedPubMedCentralCrossRef
31.
Zurück zum Zitat Itatani R, Namimoto T, Yoshimura A, et al. (2014) Clinical utility of the normalized apparent diffusion coefficient for preoperative evaluation of the aggressiveness of prostate cancer. Jpn J Radiol 32(12):685–691PubMedCrossRef Itatani R, Namimoto T, Yoshimura A, et al. (2014) Clinical utility of the normalized apparent diffusion coefficient for preoperative evaluation of the aggressiveness of prostate cancer. Jpn J Radiol 32(12):685–691PubMedCrossRef
32.
Zurück zum Zitat Woo S, Suh CH, Kim SY, Cho JY, Kim SH (2018) Head-to-head comparison between high- and standard-b-value DWI for detecting prostate cancer: a systematic review and meta-analysis. AJR 210(1):91–100PubMedCrossRef Woo S, Suh CH, Kim SY, Cho JY, Kim SH (2018) Head-to-head comparison between high- and standard-b-value DWI for detecting prostate cancer: a systematic review and meta-analysis. AJR 210(1):91–100PubMedCrossRef
33.
Zurück zum Zitat Fennessy F, Fedorov A, Vangel M, et al. (2018) Multiparametric MRI as a biomarker of response to neoadjuvant second-generation hormone therapy for localized prostate cancer- a pilot study. Proc Intl Soc Mag Reson Med 2018:26 Fennessy F, Fedorov A, Vangel M, et al. (2018) Multiparametric MRI as a biomarker of response to neoadjuvant second-generation hormone therapy for localized prostate cancer- a pilot study. Proc Intl Soc Mag Reson Med 2018:26
34.
Zurück zum Zitat Hurrell SL, McGarry SD, Kaczmarowski A, et al. (2018) Optimized b-value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging. J Med Imaging (Bellingham) 5(1):011004 Hurrell SL, McGarry SD, Kaczmarowski A, et al. (2018) Optimized b-value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging. J Med Imaging (Bellingham) 5(1):011004
35.
Zurück zum Zitat Feng Z, Min X, Margolis DJA, et al. (2017) Evaluation of different mathematical models and different b-value ranges of diffusion-weighted imaging in peripheral zone prostate cancer detection using b-value up to 4500 s/mm2. Schwentner C, ed. PLoS ONE 12(2):e0172127PubMedPubMedCentralCrossRef Feng Z, Min X, Margolis DJA, et al. (2017) Evaluation of different mathematical models and different b-value ranges of diffusion-weighted imaging in peripheral zone prostate cancer detection using b-value up to 4500 s/mm2. Schwentner C, ed. PLoS ONE 12(2):e0172127PubMedPubMedCentralCrossRef
36.
Zurück zum Zitat Purysko AS, Bittencourt LK, Bullen JA, et al. (2017) Accuracy and interobserver agreement for prostate imaging reporting and data system, version 2, for the characterization of lesions identified on multiparametric MRI of the prostate. AJR 209(2):339–349PubMedCrossRef Purysko AS, Bittencourt LK, Bullen JA, et al. (2017) Accuracy and interobserver agreement for prostate imaging reporting and data system, version 2, for the characterization of lesions identified on multiparametric MRI of the prostate. AJR 209(2):339–349PubMedCrossRef
Metadaten
Titel
Predictive role of PI-RADSv2 and ADC parameters in differentiating Gleason pattern 3 + 4 and 4 + 3 prostate cancer
verfasst von
Francesco Alessandrino
Mehdi Taghipour
Elmira Hassanzadeh
Alireza Ziaei
Mark Vangel
Andriy Fedorov
Clare M. Tempany
Fiona M. Fennessy
Publikationsdatum
31.07.2018
Verlag
Springer US
Erschienen in
Abdominal Radiology / Ausgabe 1/2019
Print ISSN: 2366-004X
Elektronische ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-018-1718-6

Weitere Artikel der Ausgabe 1/2019

Abdominal Radiology 1/2019 Zur Ausgabe

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.